These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30507896)

  • 1. Secukinumab for plaque psoriasis.
    Ordenes-Cavieres G; Andino-Navarrete R
    Medwave; 2018 Nov; 18(7):e7364. PubMed ID: 30507896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical corticosteroids or vitamin D analogues for plaque psoriasis?
    Venegas-Iribarren S; Andino R
    Medwave; 2017 Jun; 17(Suppl 2):e6981. PubMed ID: 28665918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is secukinumab effective for psoriatic arthritis with insufficient response to initial treatment?
    Venegas-Iribarren S; Andino-Navarrete R
    Medwave; 2017 Dec; 17(9):e7101. PubMed ID: 29272266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is ustekinumab effective for psoriatic arthritis with insufficient response to initial treatment?
    Venegas-Iribarren S; Andino-Navarrete R
    Medwave; 2018 Mar; 18(2):e7174. PubMed ID: 29522505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are biologics useful for nail psoriasis?
    Antúnez-Lay A; Cabrolier J; Andino-Navarrete R
    Medwave; 2016 Jan; 16 Suppl 1():e6363. PubMed ID: 26817583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
    Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
    J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do cannabinoids constitute a therapeutic alternative for anorexia nervosa?
    Contreras T; Bravo-Soto GA; Rada G
    Medwave; 2017 Dec; 17(9):e7095. PubMed ID: 29194432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
    Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
    J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of secukinumab in the treatment of psoriasis.
    Blauvelt A
    Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.
    Ryoo JY; Yang HJ; Ji E; Yoo BK
    Ann Pharmacother; 2016 May; 50(5):341-51. PubMed ID: 26783352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for nail psoriasis.
    de Vries AC; Bogaards NA; Hooft L; Velema M; Pasch M; Lebwohl M; Spuls PI
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD007633. PubMed ID: 23440816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do cannabinoids constitute a therapeutic alternative for insomnia?
    Contreras T; Bravo-Soto G; Rada G
    Medwave; 2018 Feb; 18(1):e7152. PubMed ID: 29474349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT; Shojania K; Dutz J; Tsao NW
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.